A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study

Trial Profile

A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Bipolar I disorders; Schizophrenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 30 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 28 Jul 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top